Abdelaty, Lamiaa N <br/><br/>
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.  [electronic resource] 

 -  Current drug safety  2020 
 - 53-60 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2212-3911 
<br/><br/><label>Standard No.: </label>10.2174/1574886314666191001151314  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Benzimidazoles--therapeutic use<br/>Carbamates<br/>Drug Therapy, Combination<br/>Drug-Related Side Effects and Adverse Reactions<br/>Egypt<br/>Female<br/>Fluorenes--therapeutic use<br/>Genotype<br/>Hepatitis C, Chronic--blood<br/>Humans<br/>Imidazoles--therapeutic use<br/>Liver Cirrhosis<br/>Male<br/>Middle Aged<br/>Pyrrolidines<br/>Random Allocation<br/>Sofosbuvir--therapeutic use<br/>Treatment Outcome<br/>Valine--analogs & derivatives